1. Home
  2. Companies
  3. ATH
  4. Material Events

Alterity Therapeutics (ASX:ATH) — Material Events

ASX:ATH · 18 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 16 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
16
Alterity Therapeutics Secures FDA Green Light for ATH434 Phase 3 Trial in Multiple System AtrophyMedium
Alterity Therapeutics Secures FDA Alignment on Phase 3 Trial Design for ATH434 in Multiple System Atrophy
9 June 2026 ·Clinical Trial Update ·85
Alterity Therapeutics Advances ATH434 with Strong Phase 2 Data and A$40M Capital RaiseHigh
Alterity Therapeutics posts reduced loss, reports positive Phase 2 MSA trial results for ATH434, and raises A$40 million
29 Aug 2025 ·Annual Report and Form 20-F ·85
Alterity’s ATH434 Shows Promise in Slowing Multiple System Atrophy ProgressionMedium
Alterity Therapeutics reports positive Phase 2 results for ATH434 in Multiple System Atrophy
15 Sept 2025 ·Clinical Trial Data Presentation ·85
Alterity Therapeutics Advances MSA Treatment with FDA Fast Track and Strong Phase 2 ResultsHigh
Alterity Therapeutics secures FDA Fast Track for ATH434 in MSA with positive Phase 2 data and strong cash position
30 July 2025 ·Appendix 4C Quarterly Cash Flow Report ·85
Alterity’s ATH434 Slows Progression in Advanced Multiple System AtrophyMedium
Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 in Advanced MSA
28 July 2025 ·Clinical Trial Results ·85
Alterity Advances ATH434 to Phase 3 with Promising MSA Trial DataMedium
Alterity Therapeutics Advances ATH434 to Phase 3 for Multiple System Atrophy Following Positive Phase 2 Data
19 May 2026 ·Clinical Trial Update ·85
Alterity Strengthens ATH434 Data, Eyes FDA Phase 3 Nod with $49M Cash BufferMedium
Alterity Therapeutics advances ATH434 with strong Phase 2 data, FDA Phase 3 planning, and solid cash position
30 Jan 2026 ·Appendix 4C Quarterly Cash Flow Report & Corporate Update ·85
FDA Confirms Single Phase 3 Trial Pathway for Alterity’s ATH434 in MSAMedium
FDA Confirms Registrational Pathway for Alterity's ATH434 in Multiple System Atrophy
7 July 2026 ·Regulatory Update ·85
Alterity Advances ATH434 Phase 3 Program with FDA Alignment and New Clinical DataMedium
Alterity Therapeutics advances ATH434 Phase 3 plans with FDA alignment and strong clinical data, holds A$44.53M cash
30 Apr 2026 ·Quarterly Cash Flow Report and Corporate Update ·85
Alterity Advances ATH434 with Strong Phase 2 Data and $2.4B Market PotentialMedium
Alterity Therapeutics reports positive Phase 2 data for ATH434 in MSA and secures A$54.56M cash with $2.4B market potential
31 Oct 2025 ·Appendix 4C Quarterly Cash Flow Report ·85
Alterity’s ATH434 Shows Functional Benefit in MSA Using New Composite ScaleMedium
Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 in Multiple System Atrophy
22 Apr 2026 ·Clinical Trial Data Presentation ·85
Alterity Therapeutics Advances ATH434 Phase 3 with Positive FDA FeedbackMedium
Alterity Therapeutics Secures Positive FDA Feedback on ATH434 Phase 3 Program
30 Mar 2026 ·Regulatory Update ·80
Alterity Therapeutics Secures A$20M to Propel ATH434 Toward FDA ApprovalMedium
Alterity Therapeutics Raises A$20M in Strategic Placement to Advance ATH434 Clinical Development
8 Sept 2025 ·Capital Raising ·80
ASX Probes Alterity Therapeutics Over Disclosure Missteps and Governance GapsMedium
ASX queries Alterity Therapeutics over disclosure errors; ATH admits governance lapses but denies ramping
4 Aug 2025 ·ASX Query Letter and Response ·Unexpected ·75
Alterity Advances ATH434 Phase 3 Program with FDA Endorsement on ManufacturingMedium
Alterity Therapeutics Secures Positive FDA Feedback on ATH434 Phase 3 Program for MSA
27 Apr 2026 ·Regulatory Update ·75
Alterity Therapeutics Unveils Breakthrough MRI Biomarker for Tracking MSA ProgressionMedium
Alterity Therapeutics publishes study on novel MRI biomarker for Multiple System Atrophy progression
24 July 2025 ·Research Publication Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.